Semma Therapeutics: Semma Therapeutics Announces PreClinical ProofofConcept in Two Lead Programs in Type 1 Diabetes
Stem cellderived islets successfully reduce insulin requirements in diabetic nonhuman primates Novel device successfully protects stem cellderived islets in pigs without immunosuppression Company plans to initiate two clinical trials in 2020 Semma Thera...
Read full article »
Semma Therapeutics is a biotechnology company that develops and commercializes stem cell-based therapies for the treatment of diabetes.
Read more